ALK's acquisition of the largest allergy vaccine company in the Netherlands approved

ALK has been informed that the shareholders at an extraordinary general meeting
of Fornix BioSciences (”Fornix”) today has approved ALK's proposal to acquire
the Dutch activities of Fornix' Allergy Division, Artu, for a consideration of
EUR 19.6 million (DKK 146 million). ALK made the proposal on 26 April 2010, cf.
company release No 10/2010.

The transaction will be effective on 1 July 2010, after which Artu and ALK's
Dutch subsidiary will be fully integrated. No other approvals are outstanding,
and ALK therefore considers the transaction finally approved. 

The acquisition is part of ALK's strategy of expanding its global presence and
of contributing to the consolidation of the allergy vaccine industry caused by
increased regulatory requirements to products. 

The acquisition is still expected to increase ALK's sales and earnings. The
effect on operating profit (EBIT) after transaction costs in 2010 is expected
to be slightly positive. 

ALK-Abelló A/S


Jens Bager
President and CEO


For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. + 45 4574 7901, mobile + 45 2064 1143